Drugs / Expanded haploidentical NK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05334693 | Nov 2021 → Dec 2025 overdue | acute myeloid leukemia | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Expanded haploidentical NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05334693 ↗ |
| Modality | Cell therapy | “ex vivo expanded haploidentical NK cells” NCT05334693 ↗ |
| Route | Intravenous | “two intravenous infusions of expanded haploidentical NK cells” NCT05334693 ↗ |